Skip to main content
OpenTrials
Completed

NCT Number: NCT04571008

Effect of NMN Supplementation on Organ System Biology

The goal of this proposal is to determine whether the beneficial effects of NMN on metabolic function observed in rodents applies to people.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

45 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Washington University School of Medicine

St Louis, Missouri, 63110, United States

About this study

This study is looking at the effect of the dietary supplement "Nicotinamide mononucleotide" (NMN) on key cardiovascular and metabolic functions, specifically those that are important risk factors for diabetes and cardiovascular disease.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI 25.0-50.0 kg/m²
  • Prediabetes defined as fasting plasma glucose of ≥100 mg/dL, or HbA1C ≥5.7, or HOMA-IR ≥2.5.

Exclusion criteria

  • Women who are still having menses
  • Persons who take niacin, nicotinamide, or other vitamin B3-related supplementation and are not willing to discontinue supplementation for 3 weeks before medical screening and during the entire study period
  • Persons who consume moderate-large amounts of caffeine daily (>2 cups of coffee or 8 oz caffeinated drinks per day) or consume less amounts of caffeine but believe withdrawal symptoms (e.g. headache) are likely if caffeine is stopped
  • Unstable weight (>3% change during the last 2 months before entering the study)

Treatment and study plan

Placebo

Other

Intervention will last at least 16 weeks in the form of two capsules.

Treatment

Dietary Supplement

Intervention will last at least 16 weeks in the form of two or three NMN capsules (total of 300 or 450 mg/day).

Primary outcomes

  1. Change in Muscle Insulin Sensitivity

    Time frame: After at least 16 weeks of treatment

    The outcome will be assessed during hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopic tracer infusion after intervention period.

Secondary outcomes

  1. Changes in Glucose Tolerance

    Time frame: After at least 16 weeks of treatment

    The outcome will be assessed during modified oral glucose tolerance test after the intervenion

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Collaborators

  • United States Department of Defense

Registry information

Official study title

Effect of Nicotinamide Mononucleotide (NMN) Supplementation on Organ System Biology

Acronym: VAN

Important dates

Study start
2020
Primary completion
2025
Study completion
2025
First posted
Sep 30, 2020
Registry last updated
Mar 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.